Riskpilot← Back to searchSign inGet full accessHoba Therapeutics ApS
APSActiveCVR 38231170Ole Maaløes Vej 3Research and experimental development on natural sciences and engineering · NACE 7210Est. 20165 employeeswww.hobatherapeutics.com
Revenue 2025
DKK -38,3M
+84% vs 2024
EBITDA margin
127.0%
-59% vs 2024
Equity ratio
56.5%
Financial strength
Net profit 2025
DKK -43M
-55% vs 2024
| Revenue | DKK -38,3M | +84% |
| EBITDA | DKK -48,7M | -59% |
| Net profit | DKK -43M | -55% |
| Total assets | DKK 46,1M | -50% |
| Equity | DKK 26,1M | -62% |
| Employees | 5 | — |
Legal name
Hoba Therapeutics ApS
CVR number
38231170
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
28. november 2016
Share capital
DKK 2.991.195
Employees
5 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-03-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med den adm. direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er forskning, udvikling og kommercialisering af lægemidler.
Address
Ole Maaløes Vej 3
Email
md@hobatherapeutics.com
Website
www.hobatherapeutics.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1.393 | 0 | -9.430 | -20.860 | -38.348 |
| Staff expenses | -2.900 | -2.997 | -5.980 | -9.790 | -10.351 |
| EBITDA | -1.507 | -10.179 | -15.410 | -30.650 | -48.700 |
| Depreciation & amort. | -4 | -3 | -0 | -0 | -0 |
| EBIT | -1.511 | -10.182 | -15.410 | -30.650 | -48.700 |
| Net financials | -1.491 | -2.524 | -2.616 | -2.657 | 192 |
| Profit before tax | -3.001 | -12.706 | -18.027 | -33.307 | -48.508 |
| Tax | -1.057 | -1.807 | -4.096 | -5.500 | -5.500 |
| Net profit | -1.945 | -10.899 | -13.930 | -27.807 | -43.008 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 36.461 | 19.646 | 15.288 | 91.476 | 46.100 |
| Equity | 8.184 | -18.975 | -32.905 | 69.070 | 26.062 |
| Long-term debt | 24.504 | 36.986 | 11.059 | 13.202 | 11.014 |
| Short-term debt | 928 | 1.635 | 37.134 | 9.204 | 9.024 |
| Total debt | 25.432 | 38.621 | 48.193 | 22.406 | 20.038 |
EBITDA margin
-4869984000.0%
This company
15.8%
Market median
-30822683644% vs market
20212025
Equity ratio
56.5%
This company
38.2%
Market median
+48% vs market
20212025
Return on equity
-165.0%
This company
18.4%
Market median
-997% vs market
20212025
Net profit margin
-4300828700.0%
This company
8.1%
Market median
-53096650717% vs market
20212025
Asset turnover
-0.83×
This company
1.12×
Market median
-174% vs market
20212025
Debt / equity
0.77×
This company
0.62×
Market median
+24% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via CVR / Virk · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via CVR / Virk · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via CVR / Virk · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via CVR / Virk · Period 2020-04-01 – 2021-03-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JM Chief Executive Officer | Chief Executive Officer | 2025 |
| Former (3) | ||
MD Management | Management | 2016 – 2017 |
KA Chief Executive Officer | Chief Executive Officer | 2017 – 2020 |
TM Chief Executive Officer | Chief Executive Officer | 2020 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2024 | |
| Board of Directors | 2023 | |
| Former (7) | ||
| Chairman | 2016 – 2024 | |
KH | Board of Directors | 2025 – 2026 |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2021 – 2026 | |
| Board of Directors | 2023 – 2025 | |
| Board of Directors | 2018 – 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.33–49.99% | 33.33–49.99% | 2023 | |
| Individual | 20–24.99% | 20–24.99% | 2025 | |
| Company | 10–14.99% | 10–14.99% | 2023 | |
| Individual | 10–14.99% | 10–14.99% | 2025 | |
| Individual | 10–14.99% | 10–14.99% | 2023 | |
| Individual | 5–9.99% | 5–9.99% | 2023 | |
| Company | 10–14.99% | 10–14.99% | 2016 | |
| Company | 5–9.99% | 5–9.99% | 2022 | |
| Individual | 15–19.99% | 15–19.99% | 2018 | |
| Company | 5–9.99% | 5–9.99% | 2016 | |
| Company | 15–19.99% | 15–19.99% | 2018 | |
| Individual | 5–9.99% | 5–9.99% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
Hoba Therapeutics ApS Board members of Hoba Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Morten Døssing | Management | 0 companies |
| Kenneth Ahrend Petersen | Chief Executive Officer | 0 companies |
| Jean Marcel André Combalbert | Chief Executive Officer | 0 companies |
| Torsten Meldgaard Madsen | Chief Executive Officer | 0 companies |
| Amanda Hayward | Chairman | 0 companies |
| Kuang He | Board of Directors | 0 companies |
| Thor Jespersen | Board of Directors | 0 companies |
| Lene Gerlach | Board of Directors | 0 companies |
| Gunnar Magnus Severus Modée Persson | Board of Directors | 0 companies |
| Camilla Petrycer Hansen | Board of Directors | 0 companies |
| Gonçalo Nuno Nunes da Silva Rebelo de Andrade | Board of Directors | 0 companies |
| Marie Allen Schroeder | Board of Directors | 0 companies |
| Steen Palle Petersen | Board of Directors | 0 companies |